Anovulatory Cycles in Perimenopause

Anovulatory cycles in perimenopause help explain a transition that rarely feels like a steady hormonal decline. When ovulation fails, the expected progesterone rise fails with it, while estrogen can remain high or swing sharply. Understanding this progesterone-first pattern connects unpredictable symptoms with their biology and explains why hormone changes across cycles can reveal more than a single test.

Why perimenopause feels so chaotic before anyone has an explanation

A woman’s period arrives two weeks early, then disappears for two months, then returns heavier than ever. During the same stretch, she sleeps poorly, loses her train of thought, and feels her mood shift without a clear reason. The symptoms seem to contradict one another. How can heavy bleeding and breast tenderness belong to the same transition as hot flashes and disrupted sleep?

The familiar explanation that “your hormones are dropping” leaves that question unanswered. It suggests a steady loss, yet the experience can feel like too much hormonal activity one week and too little the next. Even in the same cycle, symptoms may swing the other way. The missing explanation begins with whether ovulation happens at all.

What anovulation is and why it begins before most women expect it

Anovulation means that a cycle proceeds without the release of an egg. In perimenopause, this becomes more likely as ovarian aging changes how follicles respond to gonadotropin signaling, the hormonal signals that stimulate them. As the quantity and quality of oocytes decline, follicles become increasingly unresponsive, and some never complete ovulation. A woman can have a textbook 28-day cycle without ovulating.

That distinction separates menstrual bleeding from ovulatory function. A period records a bleeding event, but its arrival does not establish that an egg was released beforehand. Ovarian reserve also declines throughout life rather than beginning to disappear suddenly at midlife. Anovulatory cycles can therefore start years before a woman notices that her cycle length has become irregular.

The STRAW+10 classification uses a seven-day-or-greater difference in cycle length as part of how it defines early perimenopause, Stage -2. That is a useful marker of the transition, but anovulation can precede it. The calendar is not the whole picture.

Why progesterone falls first, and what that means for every cycle that follows

After a follicle releases an egg, it forms the corpus luteum, the structure responsible for almost all of the cycle’s progesterone production. Without ovulation, no corpus luteum forms. The expected progesterone rise is therefore absent. This is the core of the progesterone-first mechanism, because a cycle can lose its main source of progesterone while developing follicles continue to produce estrogen.

Either ovulation produces a corpus luteum and progesterone rises, or anovulation removes that source. As anovulatory cycles happen more often, the body has less exposure to progesterone over months and years, while estrogen may still go up and down or stay high for a time.

The Centre for Menstrual Cycle and Ovulation Research at UBC, founded and led by Scientific Director Dr. Jerilynn Prior, frames progesterone deficiency from anovulation as the first and primary hormonal shift. CeMCOR’s work challenges the assumption that perimenopause is primarily an estrogen-deficiency state. The distinction changes how symptoms can be interpreted. Along with asking whether estrogen is low, it helps to ask whether progesterone is rising to balance the estrogen the body still makes.

How estrogen becomes erratic once progesterone is no longer regulating the cycle

Unreliable ovulation also occurs within a changing feedback system, the hypothalamic-pituitary-ovarian axis. FSH rises to stimulate follicle development more aggressively, and in early perimenopause this can overstimulate remaining follicles. Estradiol can then spike above the levels usual in the reproductive phase. A follicle may produce that surge and still fail to ovulate, leaving high estrogen without the progesterone rise that would normally follow.

The next cycle can look very different. If a follicle fails to develop, estradiol may fall sharply instead. Within weeks, a woman can move from relatively high estrogen to relatively low estrogen. Breast tenderness, heavy bleeding, and bloating can give way to hot flashes, insomnia, and brain fog.

STRAW+10 places increased cycle-length variability and elevated, variable FSH in Stage -2. Stage -1 includes extended gaps between periods and extreme hormonal fluctuations, when vasomotor symptoms typically become prominent. The emphasis shifts as the transition advances. High-estrogen symptoms tend to be more prominent early, while low-estrogen symptoms, including vaginal dryness, joint pain, and brain fog, become more dominant later. These broad patterns allow for variation in how adjacent cycles will feel.

Why a single hormone test taken at one point in time cannot capture this pattern

What does a hormone result mean when the underlying system is changing from week to week? A single estrogen or FSH measurement describes hormone levels only at the moment of collection. FSH can cross a conventional menopausal threshold and return to a normal range within weeks. A normal result may therefore simply capture a less revealing point in the fluctuation during perimenopause.

There is also a feedback effect that can make the result particularly misleading. Elevated estradiol in early perimenopause can suppress FSH, so an apparently normal FSH value may occur during substantial hormonal instability. The result need not be inaccurate to invite the wrong conclusion.

The same problem can arise with progesterone when the test’s timing in the cycle is unknown. A low result alone cannot show whether the expected post-ovulation rise failed to happen or the sample was taken before that rise was due. Timing changes the meaning of the number. The useful response is not to abandon testing, but to ask what a test can establish and what requires observation over time.

What tracking hormone levels across multiple cycles reveals that a snapshot cannot

Tracking across cycles can show whether progesterone was low just once or failed to rise as expected time after time. It also shows whether estrogen swings occur in the same periods as changes in sleep or anxiety. Sequence becomes part of the evidence. Instead of interpreting each result alone, the clinician can consider how the values relate to ovulation, bleeding, and symptoms.

The Study of Women’s Health Across the Nation, a multi-site longitudinal study spanning more than 25 years, found that FSH rises gradually over years before the final period. Estradiol stays much the same until about 2 years before the final period, when it drops sharply, though it goes up and down more in some subgroups. That population trajectory does not mean every individual cycle is stable.

Oova’s research identified an early progesterone rise in the follicular phase as a potential predictor of anovulation. A single mid-luteal draw would miss that sequence. Its sleep and hormone research also found that daily tracking linked sleep duration and anxiety significantly with estrogen (E3G) patterns, with no significant differences found for LH or PdG. These findings describe associations and a potential predictor, with diagnosis requiring more than a home measurement alone. Their value lies in revealing timing and relationships that a one-point assessment cannot show.

The downstream effects of unchecked anovulation that go beyond irregular periods

The hormonal shifts associated with anovulation extend beyond the timing and heaviness of bleeding. Studies have linked bone loss, sleep disruption, and mood disturbance to these changes in hormones. The consequences reach beyond the reproductive system. Yet a link does not mean that every symptom or later health problem can be attributed to anovulation alone, particularly when several hormonal changes occur together.

A 2025 BMC Women’s Health study that used Global Burden of Disease data found that, from 1990 to 2021, there was a rise in the global age-standardized disability-adjusted life year rate for anxiety disorders in perimenopausal women. Its projections to 2035 showed a 40.67% increase from the 2021 level. The authors linked anxiety to changes in hormones that affect the feedback mechanisms the body uses to regulate itself. That population finding establishes the scale of the burden, but it does not isolate anovulation as the cause of the increase.

Sleep creates a more immediate feedback loop. Hormonal fluctuation can disrupt sleep, while disturbed sleep can worsen other perimenopausal symptoms. The effect is not confined to the night. Mood and cognitive difficulties may become part of an interconnected experience rather than separate complaints, which helps explain why a disrupted cycle can coincide with a much broader loss of day-to-day stability.

Why perimenopausal symptoms are so often misread as anxiety, depression, or stress

Mood instability, sleep disruption, cognitive difficulty, palpitations, and fatigue overlap closely with presentations of anxiety and depression. Those diagnoses are also more familiar to many clinicians than the nuances of perimenopausal hormone patterns. The diagnostic difficulty is therefore genuine. Thyroid dysfunction has several of the same symptoms, so other causes still need to be considered when perimenopause is recognized.

Hormonal volatility affects neurotransmitter systems, HPA axis tone, and the body’s stress response, meaning physiological and psychiatric changes can be intertwined. Anxiety is not made less real by a hormonal contribution. The error is treating a mental health explanation as necessarily excluding a reproductive one, or assuming that a hormonal explanation excludes a coexisting condition.

A 2025 national survey commissioned by Biote found that nearly 40% of women who sought care for perimenopause symptoms reported feeling misdiagnosed. Among those prescribed medication for conditions like depression, a similar share believed they had not been appropriately diagnosed. These reports reflect patients’ experiences, with rates of diagnostic error still requiring independent verification. They nevertheless name a real failure in care as experienced by women whose explanation or treatment did not fit their concerns.

Understanding the mechanism offers a way into a more specific conversation. Rather than presenting only a collection of symptoms, a woman can describe their relationship to bleeding patterns and ask whether ovulation and progesterone production are changing. That context gives the clinician another hypothesis to examine. It supports self-advocacy without making clinicians adversaries or reducing complex symptoms to a single cause.

What to ask for, and what to track, once you understand what is actually happening

A woman who wants to understand what is happening can ask whether ovulation is occurring, whether progesterone is rising as expected, and how estradiol changes across cycles. Those questions give testing a defined purpose. Progesterone helps assess the luteal rise, estradiol helps describe the swing, and FSH provides context about the pituitary’s compensatory response. Their interpretation belongs with cycle timing and symptoms.

Timing deserves a direct discussion with the clinician. FSH is most informative when drawn in the early follicular phase, on cycle days 2–5. Low progesterone on day 5 is expected, while a low result on day 21 in a 28-day cycle is a signal that needs interpretation. It is consistent with anovulation, but cycle context remains essential. Tracking bleeding, hormone patterns, sleep, and mood across multiple cycles can help distinguish a repeated pattern from an unrepresentative week.

Clinician review is essential to that process. The same estradiol value can mean something different depending on cycle timing, FSH, and the symptom pattern, so raw numbers are not an answer by themselves. Oova’s tracking research takes this approach by looking at how hormone patterns line up with cycle events and what women feel each day. Being able to say that anovulatory cycles may be occurring and progesterone may not be rising as expected opens a different conversation with a clinician.